Pharmacy

Your Article Summary

See Latest Articles

Biovail Provides Update on Pimavanserin Collaborative Development Program
BioVail Corporation, 10/07/09

Biovail Corporation provided an update on its Phase III program with pimavanserin for Parkinson’s disease psychosis, which is being pursued in collaboration with ACADIA Pharmaceuticals Inc. Following the announcement on September 1st of disappointing top–line results from the first Phase III PDP trial, Biovail and ACADIA remain committed to the successful development of pimavanserin and have established a development strategy that they believe will strengthen the PDP program.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
PharmacoEconomics, 11/24/09

Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09

 See all of Drug Trials

Today in Neuro/Psych pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Propylene Glycol Accumulation in Critically Ill Patients Receiving Continuous Intravenous Lorazepam Infusions
Annals of Pharmacotherapy, 11/25/09

Effect of cilnidipine vs losartan on cerebral blood flow in hypertensive patients with a history of ischemic stroke: a randomized controlled trial
Acta Neurologica Scandinavica, 11/25/09

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09

 See all of Neuro/Psych pharmacology